Seltorexant治疗失眠障碍的疗效与安全性随机临床试验
这项随机双盲安慰剂和佐匹克隆对照的剂量探索研究纳入无精神共病的失眠成人,评估seltorexant 5、10、20 mg连续14天的多导睡眠图疗效。10 mg和20 mg在首夜及第13夜改善入睡与睡眠维持,且耐受性总体良好。
要点
- seltorexant 10 mg和20 mg改善首夜及第13夜入睡潜伏期和入睡后觉醒。
- 20 mg对首夜入睡潜伏期优于佐匹克隆,第13夜佐匹克隆疗效减退。
- seltorexant合并剂量组治疗中出现不良事件低于安慰剂和佐匹克隆。
核心结论
- 在无精神共病的失眠成人中,seltorexant 10 mg和20 mg连续14天改善睡眠启动与维持,且总体耐受良好。
研究设计与样本
- 纳入18-64岁成人及65-85岁老年人,失眠严重指数≥15且无精神共病,按1:1:1:1:1随机接受seltorexant 5、10、20 mg或安慰剂或佐匹克隆5-10 mg,每晚口服14天。
- 共364例受试者接受治疗,平均(SD)年龄57.8(12.4)岁,女性246例(67.6%)。
主要发现
- 首夜入睡潜伏期剂量反应关系显著,4个预设模型趋势检验t统计量均≥3.99且校正P值均<.001。
- 首夜入睡潜伏期seltorexant 10 mg与安慰剂比较LSM比值为0.64(90%CI 0.51-0.81),20 mg为0.51(90%CI 0.41-0.64),20 mg与佐匹克隆比较为0.71(90%CI 0.57-0.88)。
- 首夜前6小时入睡后觉醒剂量反应关系显著,4个预设模型趋势检验t统计量均≥3.99且校正P值均<.001;10 mg与安慰剂比较LSM比值为0.68(90%CI 0.55-0.85),20 mg为0.60(90%CI 0.48-0.74)。
- 第13夜seltorexant 10 mg和20 mg对首夜入睡潜伏期与前6小时入睡后觉醒的改善维持,佐匹克隆则减退;与佐匹克隆比较,10 mg和20 mg分别改善入睡潜伏期30%和28%,20 mg改善前6小时入睡后觉醒31%。
- seltorexant合并剂量组治疗中出现不良事件为73/216(33.8%),低于安慰剂37/75(49.3%)和佐匹克隆31/73(42.5%);双盲期2例发生严重不良事件(seltorexant 20 mg组1例,佐匹克隆组1例)。
关键数值与推荐
- 失眠严重指数评分≥15且无精神共病作为纳入标准。
- 主要和关键次要结局为首夜入睡潜伏期和前6小时入睡后觉醒的剂量反应关系,其他次要结局包括第13夜入睡潜伏期和前6小时入睡后觉醒。
- 因基線入睡潜伏期和前6小时入睡后觉醒呈不对称分布,采用对数转换并以回转换最小二乘均值比值表达组间比较。
临床怎么用
- 对于无精神共病的失眠成人,seltorexant 10 mg和20 mg可作为改善入睡与睡眠维持的候选剂量,但需结合个体情况评估。
- seltorexant 5 mg组有3例、20 mg组有1例因无症状心电图相关不良事件停药,临床使用中应关注心电图监测。
局限性
- 研究为剂量探索设计,样本量有限,各剂量组仅71-75例。
- 研究排除精神共病患者,结果不能直接外推至精神心理科共病失眠人群。
- 研究数据投稿时间受内部战略决策影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Existing pharmacological treatments for insomnia have significant limitations. OBJECTIVE: To assess the effective dose range, safety, and tolerability of the novel selective orexin-2 receptor antagonist seltorexant in insomnia disorder. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, active- and placebo-controlled, dose-finding, polysomnography study was conducted from November 2017 to April 2019 at 55 sites in 6 countries and analyzed in August 2019. The timeline for submission of this data for publication was impacted by internal strategic decision-making. Adults (aged 18-64 years) and older adults (aged 65-85 years) with insomnia (Insomnia Severity Index score ≥15) and no psychiatric comorbidity were included. INTERVENTIONS: Participants were randomized 1:1:1:1:1 to receive nightly oral-seltorexant (5 mg, 10 mg, or 20 mg), placebo, or zolpidem (5-10 mg) for 14 days. MAIN OUTCOMES AND MEASURES: Primary and key secondary outcomes included the dose-response relationship of night 1 latency to persistent sleep (LPS) and wake after sleep onset over the first 6 hours (WASO-6). Other secondary outcomes included night 13 LPS and WASO-6. Due to asymmetrical distributions of LPS and WASO-6 at baseline, log transformation was applied and results were expressed as back-transformed least-squares mean (LSM) ratios for comparisons between groups. RESULTS: Overall, 364 participants (mean [SD] age, 57.8 [12.4] years; 246 [67.6%] female) received seltorexant, 5 mg (n = 71), 10 mg (n = 74), or 20 mg (n = 71); placebo (n = 75); or zolpidem (n = 73). The night 1 dose-response relationship for LPS was significant (with trend test t statistics ≥3.99 and adjusted P values <.001 for all 4 prespecified models), with greater improvements in seltorexant, 10 mg and 20 mg, vs placebo (10 mg: LSM ratio, 0.64; 90% CI, 0.51-0.81; 20 mg: LSM ratio, 0.51; 90% CI, 0.41-0.64) and in seltorexant, 20 mg, vs zolpidem (LSM ratio, 0.71; 90% CI, 0.57-0.88). The night 1 dose-response relationship for WASO-6 was also significant, with trend test t statistics ≥3.99 and adjusted P values <.001 for all 4 prespecified models (seltorexant, 10 mg: LSM ratio, 0.68; 90% CI, 0.55-0.85; seltorexant, 20 mg: LSM ratio, 0.60; 90% CI, 0.48-0.74). Night 1 LPS and WASO-6 improvements were maintained on night 13 for seltorexant, 10 mg and 20 mg, but diminished for zolpidem. On night 13, compared with zolpidem, seltorexant, 10 mg and 20 mg, improved LPS by 30% and 28%, respectively, and seltorexant, 20 mg, improved WASO-6 by 31%. Treatment-emergent adverse events (TEAEs) were lower across the combined seltorexant doses (73/216 [33.8%]) relative to placebo (37/75 [49.3%]) and zolpidem (31/73 [42.5%]). Two participants experienced serious TEAEs during the double-blind phase (1 in the seltorexant, 20 mg, group and 1 in the zolpidem group). Three participants in the seltorexant, 5 mg, and 1 in the seltorexant, 20 mg, group experienced asymptomatic electrocardiogram-related TEAEs leading to discontinuation. CONCLUSIONS AND RELEVANCE: Among participants with insomnia in this study, seltorexant, 10 mg and 20 mg, improved sleep initiation and maintenance throughout 14 days of treatment. Seltorexant was generally well tolerated. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03375203.
引用
- Mesens S, Krystal AD, Melkote R, et al. Efficacy and Safety of Seltorexant in Insomnia Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 40802194. doi:10.1001/jamapsychiatry.2025.1999
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。